Cancer

Key Priorities

Throughout 2024 and beyond, we will deliver the North East and Yorkshire Genomics Cancer Strategy in close collaboration with each of the four Cancer Alliances in the region to deliver faster diagnosis and treatment for patients with cancer.

To help focus and co-ordinate our efforts, we have set up a new Genomics Clinical Operational Group for Cancer, led by Professor Alastair Greystoke, Clinical Director for Cancer in the NEY GMS.

Initial pathways for review and improvement are Lung, Colorectal and Prostate Cancer. But others will follow to ensure equitable access to genomic testing and treatment for patients across the region.

The main challenge is to ensure that results for genetic cancer tests are returned to clinical teams (and shared with patients) to guide treatment as soon as possible. This challenge can only be achieved by working together with colleagues from all parts of the system – and of course, with patients who will ultimately benefit from the effective inclusion of genomics in their care.

Our Work in Cancer Genomics

In addition to the priorities above, the NEY GMS is leading and supporting the delivery of the following workstreams:

• Circulating Tumour DNA (ctDNA Liquid Biopsy) Pilot
• Haemato-Oncology Genomic Network of Excellence

Legacy workstreams in cancer are:

• Lynch Syndrome
• DPYD Testing

Developing the Workforce in Cancer Genomics

To develop the capacity and capability of the workforce to deliver the best possible care for patients with cancer, the NEY GMS provides a raft of targeted learning opportunities. These include pathway-specific Lunch and Learn events, the development of Clinical Pathway Initiatives (CPIs), signposting clinicians to practical guides such as Oncology GeNotes and providing access to latest resources.

Go to For Professionals for more information.